江蘇吳中(600200.SH):蘇州製藥廠獲利奈唑胺葡萄糖注射液藥品註冊證書
格隆匯9月17日丨江蘇吳中(600200.SH)公佈,近日,公司全資子公司江蘇吳中醫藥集團有限公司下屬分支機構江蘇吳中醫藥集團有限公司蘇州製藥廠收到了國家藥監局核准簽發的利奈唑胺葡萄糖注射液《藥品註冊證書》。
利奈唑胺是一種細菌蛋白質合成的抑制劑,其主要作用機制不同於氯黴素和林可黴素一樣抑制肽基轉移酶,主要通過與P位點結合,從而抑制細菌起始複合物的形成。這種獨特的結構和作用機制,決定它與其他抗菌藥物不易產生交叉耐藥,對肽基轉移酶抑制劑耐藥的細菌依然有效。
利奈唑胺用於治療甲氧西林耐藥的陽性菌引起的感染,也是各國臨牀指南一致推薦的重症抗感染用藥。目前上市的劑型有片劑(規格:600mg)、葡萄糖注射液(規格:100ml:利奈唑胺200mg與葡萄糖4.57g、300ml:利奈唑胺600mg與葡萄糖13.7g)、幹混懸劑(5ml:100mg(每瓶含利奈唑胺3g))和氯化鈉注射液(規格:600mg/300ml)。
根據PDB藥物綜合數據庫的重點城市醫院典型醫院用藥數據顯示,利奈唑胺葡萄糖注射液2019年度銷售金額約6.86億元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.